Merck and Eisai announce Phase 3 LITESPARK-011 results for Welireg

Merck and Eisai announced first results from the Phase 3 LITESPARK-011 trial evaluating Welireg plus Lenvima in advanced renal cell carcinoma; the data are being presented as a late-breaking oral abstract at the 2026 ASCO Genitourinary Cancers Symposium.

Merck and Eisai announced first presentation of results from the Phase 3 LITESPARK-011 trial evaluating a dual oral regimen of Welireg plus Lenvima for advanced renal cell carcinoma. The trial enrolled patients whose disease progressed on or after anti-programmed death receptor-1/programmed death-ligand 1 therapy. These data are being presented as a late-breaking oral abstract at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium. The results are included in the official ASCO GU Press Program. Key details: - The Phase 3 LITESPARK-011 trial evaluated Welireg, a hypoxia-inducible factor-2 alpha inhibitor, in combination with Lenvima, a multireceptor tyrosine kinase inhibitor discovered by Eisai. - The study population comprised patients with advanced renal cell carcinoma whose disease progressed after anti-PD-1/PD-L1 therapy. - Data were presented as a late-breaking oral abstract at the 2026 ASCO Genitourinary Cancers Symposium and appear in the official press program. - The announcement was made jointly by Merck (MSD outside the United States and Canada) and Eisai. Summary: The companies presented Phase 3 LITESPARK-011 results at a specialist oncology meeting and documented the findings in the ASCO GU program. Undetermined at this time.